Oscar Health, Inc.

Based on the comprehensive analysis, OSCR presents a highly unfavorable investment case at this time.

Technically, the stock is in a pronounced downtrend, significantly underperforming the market with deep losses from its highs. Fundamentally, the picture is weak, marked by declining revenues, collapsing profit margins, and deeply negative returns on equity and assets, indicating severe operational challenges. Although the company's debt level is manageable, its poor profitability and negative valuation metrics make it impossible to justify a premium.

Recommendation: NOT WORTH BUYING / SELL The combination of persistent negative price momentum, deteriorating fundamentals, and a complete lack of profitability creates a high-risk profile with no clear catalyst for a near-term recovery. While the stock is technically oversold, the fundamental headwinds are too significant, suggesting further downside risk is more likely than a sustainable rebound. Investors should await clear signs of operational improvement and a return to profitability before considering a position.

RockFlow Model Forecast: Three Scenarios for 2026

Based on the comprehensive analysis provided, the 12-month outlook for OSCR is bearish. The primary catalysts for a potential recovery—such as a meaningful turnaround in revenue trends and a path back to profitability—are currently absent, leaving no clear positive drivers on the horizon. The significant risks are overwhelming and include the persistent downtrend in its share price, deteriorating fundamentals with declining revenue and negative returns, and the high likelihood of continued underperformance. Given the severe operational challenges and lack of analyst targets, the stock faces substantial downside risk, with a failure to stabilize likely leading to a test of lower price levels.

Wall Street Consensus

Most Wall Street analysts are optimistic about Oscar Health, Inc.'s 12-month outlook, with consensus target around $13.42, indicating expected upside potential.

Overall, OSCR has investment potential but also faces challenges. Here are key factors to weigh before investing.

OSCR has demonstrated significant volatility with materially negative performance across multiple timeframes.

The stock has declined substantially over both one-month (-19.59%) and three-month (-8.15%) periods, significantly underperforming the broader market by 8.2% over the recent quarter despite its high beta of 1.898 suggesting amplified moves. Currently trading at $13.42, OSCR sits approximately 20% above its 52-week low but remains 44% below its annual high, indicating the stock is technically oversold given the substantial 45.53% maximum drawdown from its peak.

Revenue & Profitability: OSCAR's Q4 2025 performance shows a concerning sequential decline, with revenue decreasing to $2.81 billion from $2.99 billion in Q3. Profitability has deteriorated significantly, with the gross profit margin falling sharply from 13.4% to 6.6%, leading to deeply negative operating and net income margins. This indicates severe pressure on the company's core operations and an inability to translate revenue into profit.

Financial Health: The debt position appears manageable with a low debt-to-equity ratio of 0.44 and a strong interest coverage ratio exceeding 300. However, liquidity is concerning with a current ratio below 1.0, suggesting potential short-term obligations challenges. The positive operating cash flow to sales ratio of 24% is a mitigating factor for cash generation despite the negative earnings.

Operational Efficiency: Efficiency metrics are problematic, with a deeply negative Return on Equity of -36.1% and a negative Return on Assets of -5.6%, indicating poor utilization of investor capital and assets. The asset turnover of 0.44 suggests moderate efficiency in generating revenue from its asset base, but this is overshadowed by the significant negative returns on capital employed.

Valuation Level OSCR's negative trailing and forward PE ratios indicate the company is currently unprofitable on a GAAP earnings basis, making a traditional over/undervalued assessment based on earnings inapplicable. The negative EV/EBITDA further confirms that its core operational profitability (EBITDA) is also negative. While the Price-to-Book ratio of 4.07 suggests the market values the company's equity at a significant premium to its accounting net asset value, the fundamentally negative earnings metrics are the primary concern for valuation.

Peer Comparison A direct peer comparison is not feasible as industry average data is unavailable for contextualizing OSCR's metrics. Furthermore, standard valuation comparisons like PE and EV/EBITDA are rendered meaningless when the company's figures are negative, as they cannot be benchmarked against a positive industry average. The analysis is therefore limited to an intrinsic review of the company's unprofitable state rather than a relative market assessment.

Volatility Risk: OSCR exhibits high volatility risk, with a beta of 1.898 indicating it is approximately 90% more volatile than the broad market. This elevated sensitivity is further underscored by a substantial one-year maximum drawdown of -45.53%, highlighting its potential for significant price declines during market downturns.

Other Risks: While the apparent absence of short interest suggests a lack of significant negative speculative pressure, it does not eliminate other potential risks. Investors should still consider factors such as the stock's trading liquidity and any company-specific operational or industry-related challenges not captured by this metric.